Valeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013.  Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.

The offer documents will be amended to reflect the new offer price of $24.00 per share.  The expiration date of the tender offer will remain 12:00 midnight, New York City time, on April 23, 2013. The tender offer is conditioned on the tender of a majority of Obagi’s shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of Valeant will merge with Obagi and the outstanding Obagi shares not tendered in the tender offer will be converted into the right to receive the same $24.00 per share in cash paid in the tender offer.  Obagi’s board of directors has unanimously approved the amended transaction.